More on Pfizer Q4: Guidance in line

Pfizer (PFE) net profit drops 59% to $2.57B from $6.32B a year earlier, which included a gain of $4.8B related to the divestiture of the company's nutrition operations.

Revenue breakdown: Primary Care -8%, Specialty Care -5%, established products +6%, Consumer Healthcare +2%, Oncology +29%.

Emerging markets revenues +9%.

Expects adjusted 2014 EPS of $2.20-2.30 vs consensus of $2.28, and adjusted revenues of $49.2-51.2B vs $49.74B and $51.58B in 2013.

Repurchased $4.6B of stock in Q4, $16.3B in FY.

Shares +2.8%. (PR)


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs